Hyperspectral imaging for early detection of Alzheimer's disease

Patent metadata

Field	Value
Publication number	US-11819276-B2
Application number	US-202217939566-A
Country	US
Kind code	B2
Filing date	Sep 7, 2022
Priority date	Dec 9, 2011
Publication date	Nov 21, 2023
Grant date	Nov 21, 2023

Abstract

Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.

First claim

What is claimed is:

1. A system for spectral imaging, the system comprising:
a light source for illuminating an eye tissue of a subject over a range of wavelengths;
one or more detectors for detecting light reflected by the eye tissue; and
a processor running a software comprising instructions to:
obtain spectral data of the eye tissue over the range of wavelengths from the light detected by the one or more detectors; and
analyze the spectral data at multiple light bands over the range of wavelengths to determine whether the spectral data is indicative of at least one of amyloidopathy or amyloidosis in the subject.

2. The system of claim 1 , wherein the software is configured to determine whether the spectral data is indicative of a formation of β-amyloid aggregates.

3. The system of claim 2 , wherein the β-amyloid aggregates comprise soluble β-amyloid aggregates.

4. The system of claim 2 , wherein the β-amyloid aggregates are formed in one or more of a brain, eye, or central nervous system of the subject.

5. The system of claim 1 , wherein the range of wavelengths used to obtain the spectral data are in a visible near infrared (VNIR) range.

6. The system of claim 1 , wherein the spectral data is hyperspectral data.

7. The system of claim 1 , wherein the spectral data is obtained from a hyperspectral image of the eye tissue over the range of wavelengths.

8. The system of claim 1 , wherein the software further comprises instructions to compare the spectral data of the eye tissue to at least a first previous spectral data obtained from the eye tissue of the subject at an earlier point in time, wherein significant spectral differences between the spectral data of the eye tissue and the first previous spectral data obtained from the eye tissue indicates the subject has one or more disorders resulting from at least one of amyloidopathy or amyloidosis or is predisposed for developing one or more disorders resulting from at least one of amyloidopathy or amyloidosis.

9. The system of claim 1 , wherein the software further comprises instructions to compare the spectral data from the subject to a control spectral data and to a disorder reference spectral data to determine whether the spectral data comprises spectral differences that are indicative of one or more disorders resulting from at least one of amyloidopathy and or amyloidosis.

10. The system of claim 1 , wherein the software further comprises instructions to compare the spectral data of the eye tissue to at least a first previous spectral data obtained from the eye tissue of the subject at an earlier point in time, wherein a decrease in formation of soluble β-amyloid aggregates is indicative of an effective treatment of one or more disorders resulting from at least one of amyloidopathy or amyloidosis.

11. The system of claim 1 , wherein the spectral data is obtained non-invasively and without administration of dyes for detection of β-amyloid aggregation.

12. The system of claim 1 , wherein at least one of amyloidopathy or amyloidosis is indicative of presence or onset of one or more of Alzheimer's disease, cerebral amyloid angiopathy, familial amyloid polyneuropathy, Parkinsons' disease, Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.

13. The system of claim 1 , wherein the light source is a halogen light source.

14. The system of claim 1 , further comprising an objective lens configured to collect light reflected by the eye tissue.

15. The system of claim 1 , further comprising a dispersive element.

16. The system of claim 15 , wherein the dispersive element comprises a prism.

17. A system for spectral imaging, the system comprising:
a light source for illuminating an eye tissue of a subject over a range of wavelengths;
one or more detectors for detecting light reflected by the eye tissue; and
a processor running a software comprising instructions to:
obtain spectral data of the eye tissue over the range of wavelengths from the light detected by the one or more detectors; and
analyze the spectral data at multiple light bands over the range of wavelengths to determine whether the spectral data is indicative of a formation of amyloid aggregates.

18. The system of claim 17 , wherein the range of wavelengths used to obtain the spectral data are in a visible near infrared (VNIR) range.

19. The system of claim 17 , wherein the spectral data is hyperspectral data.

20. The system of claim 17 , wherein the spectral data is obtained from a hyperspectral image of the eye tissue over the range of wavelengths.

21. The system of claim 17 , wherein the amyloid aggregates are indicative of a disorder or a predisposition associated with at least one of amyloidopathy or amyloidosis in the subject, wherein the disorder is cerebral amyloid angiopathy, familial amyloid polyneuropathy, Alzheimer's disease, Parkinson's disease (PD), Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.

22. The system of claim 21 , wherein the software further comprises instructions to compare the spectral data of the eye tissue to at least a first previous spectral data obtained from the eye tissue of the subject at an earlier point in time, wherein significant spectral difference between the spectral data of the eye tissue and the first previous spectral data obtained from the eye tissue indicates the subject has PD or is predisposed for developing PD.

23. The system of claim 21 , wherein the software further comprises instructions to compare the spectral data from the subject to a control spectral data and to a PD reference spectral data to determine whether the spectral data comprises spectral differences that are indicative of PD.

24. The system of claim 21 , wherein the software further comprises instructions to compare the spectral data of the eye tissue to at least a first previous spectral data obtained from the eye tissue of the subject at an earlier point in time, wherein a decrease in information of soluble β-amyloid aggregates is indicative of an effective treatment of PD.

25. A system for spectral imaging, the system comprising:
a light source for illuminating a cell over a range of wavelengths;
one or more detectors for detecting light reflected by the cell; and
a processor running a software comprising instructions to:
obtain spectral data of the cell over the range of wavelengths from the light detected by the one or more detectors; and
analyze the spectral data at multiple light bands over the range of wavelengths to determine whether the spectral data is indicative of a progression of one or more disorders associated with at least one of amyloidopathy or amyloidosis.

26. The system of claim 25 , wherein the one or more disorders comprise cerebral amyloid angiopathy, familial amyloid polyneuropathy, Alzheimer's disease, Parkinson's disease (PD), Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.

Assignees

• Univ Minnesota

Inventors

• Vince Robert
• More Swati Sudhakar

Classifications

• A61B3/12 Primary

  for looking at the eye fundus, e.g. ophthalmoscopes (A61B3/13 takes precedence) · CPC title

• A61B3/14

  Arrangements specially adapted for eye photography · CPC title

• A61B5/4848

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title

• A61K38/063

  Glutathione · CPC title

• G01J3/00

  Spectrometry; Spectrophotometry; Monochromators; Measuring colours · CPC title